Rice Hall James & Associates LLC Has $35.51 Million Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Rice Hall James & Associates LLC lowered its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 770,667 shares of the company’s stock after selling 22,633 shares during the quarter. Establishment Labs makes up 1.9% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 9th largest position. Rice Hall James & Associates LLC owned about 2.75% of Establishment Labs worth $35,505,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in ESTA. R Squared Ltd bought a new position in Establishment Labs in the 4th quarter worth about $36,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Establishment Labs during the 3rd quarter valued at about $127,000. Black Swift Group LLC bought a new stake in shares of Establishment Labs during the 3rd quarter valued at about $312,000. Verition Fund Management LLC boosted its position in shares of Establishment Labs by 22.8% during the 3rd quarter. Verition Fund Management LLC now owns 9,400 shares of the company’s stock valued at $407,000 after acquiring an additional 1,746 shares during the last quarter. Finally, Maven Securities LTD bought a new stake in shares of Establishment Labs during the 3rd quarter valued at about $433,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA opened at $36.08 on Tuesday. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -13.98 and a beta of 1.12. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. Establishment Labs Holdings Inc. has a 1-year low of $28.16 and a 1-year high of $60.12. The stock’s 50-day moving average is $38.72 and its 200 day moving average is $41.46.

Analyst Ratings Changes

Separately, Stephens upgraded Establishment Labs to a “strong-buy” rating in a research report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $60.60.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.